JP6516759B2 - 安定化エフィナコナゾール組成物 - Google Patents

安定化エフィナコナゾール組成物 Download PDF

Info

Publication number
JP6516759B2
JP6516759B2 JP2016546886A JP2016546886A JP6516759B2 JP 6516759 B2 JP6516759 B2 JP 6516759B2 JP 2016546886 A JP2016546886 A JP 2016546886A JP 2016546886 A JP2016546886 A JP 2016546886A JP 6516759 B2 JP6516759 B2 JP 6516759B2
Authority
JP
Japan
Prior art keywords
composition
less
amount
edta
efinaconazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016546886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532722A5 (enExample
JP2016532722A (ja
Inventor
バルシャ バット
バルシャ バット
ナヤン デサイ
ナヤン デサイ
ラダクリシュナン ピッライ
ラダクリシュナン ピッライ
Original Assignee
ダウ ファーマシューティカル サイエンシーズ，インコーポレイティド
ダウ ファーマシューティカル サイエンシーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52777446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6516759(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ダウ ファーマシューティカル サイエンシーズ，インコーポレイティド, ダウ ファーマシューティカル サイエンシーズ，インコーポレイティド filed Critical ダウ ファーマシューティカル サイエンシーズ，インコーポレイティド
Publication of JP2016532722A publication Critical patent/JP2016532722A/ja
Publication of JP2016532722A5 publication Critical patent/JP2016532722A5/ja
Application granted granted Critical
Publication of JP6516759B2 publication Critical patent/JP6516759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2016546886A 2013-10-03 2014-10-02 安定化エフィナコナゾール組成物 Active JP6516759B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886569P 2013-10-03 2013-10-03
US61/886,569 2013-10-03
US201461922867P 2014-01-01 2014-01-01
US61/922,867 2014-01-01
PCT/US2014/058911 WO2015051183A1 (en) 2013-10-03 2014-10-02 Stabilized efinaconazole compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019041262A Division JP6774518B2 (ja) 2013-10-03 2019-03-07 安定化エフィナコナゾール組成物

Publications (3)

Publication Number Publication Date
JP2016532722A JP2016532722A (ja) 2016-10-20
JP2016532722A5 JP2016532722A5 (enExample) 2017-11-09
JP6516759B2 true JP6516759B2 (ja) 2019-05-22

Family

ID=52777446

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016546886A Active JP6516759B2 (ja) 2013-10-03 2014-10-02 安定化エフィナコナゾール組成物
JP2019041262A Active JP6774518B2 (ja) 2013-10-03 2019-03-07 安定化エフィナコナゾール組成物
JP2020118180A Pending JP2020169207A (ja) 2013-10-03 2020-07-09 安定化エフィナコナゾール組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019041262A Active JP6774518B2 (ja) 2013-10-03 2019-03-07 安定化エフィナコナゾール組成物
JP2020118180A Pending JP2020169207A (ja) 2013-10-03 2020-07-09 安定化エフィナコナゾール組成物

Country Status (13)

Country Link
US (4) US9662394B2 (enExample)
EP (1) EP3052487B1 (enExample)
JP (3) JP6516759B2 (enExample)
KR (1) KR102320051B1 (enExample)
CN (2) CN105683184B (enExample)
AU (1) AU2014329421B2 (enExample)
CA (1) CA2924748C (enExample)
IL (1) IL244850B (enExample)
MX (1) MX363386B (enExample)
MY (1) MY179756A (enExample)
PH (1) PH12016500586B1 (enExample)
SG (1) SG11201602596UA (enExample)
WO (1) WO2015051183A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
WO2015051183A1 (en) 2013-10-03 2015-04-09 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
CN106918672B (zh) * 2015-12-28 2021-02-09 中美华世通生物医药科技（武汉）有限公司 利用hplc测定艾氟康唑原料药及其制剂中有关物质的方法
JPWO2018110693A1 (ja) * 2016-12-16 2019-10-24 株式会社カネカ 爪白癬治療剤
WO2019077163A2 (en) * 2017-10-20 2019-04-25 Galenicum Health S.L. PHARMACEUTICAL DEVICE
JP7430070B2 (ja) * 2019-02-08 2024-02-09 沢井製薬株式会社 エフィナコナゾール含有爪外用液
KR102352960B1 (ko) * 2019-06-07 2022-01-19 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
KR102060546B1 (ko) * 2019-06-07 2019-12-30 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
KR20210032665A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제 및 항산화제의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032672A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 에피나코나졸을 함유하는 안정화된 약학 조성물
WO2021054533A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054535A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제, 항산화제, 및 산의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054531A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 항산화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032662A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR102266145B1 (ko) 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR20220119363A (ko) 2019-12-24 2022-08-29 가껭세이야꾸가부시기가이샤 에피나코나졸을 함유하는 의약
KR102394599B1 (ko) * 2020-03-19 2022-05-06 동아에스티 주식회사 에피나코나졸을 함유하는 국소 투여용 약학 조성물
EP4161490A1 (en) 2020-06-03 2023-04-12 The Materia Company Limited Stable formulation of efinaconazole
JP7664026B2 (ja) * 2020-08-06 2025-04-17 沢井製薬株式会社 エフィナコナゾール含有爪外用液
JP2022547755A (ja) * 2020-08-14 2022-11-16 ビーエルアンドエイチ カンパニー，リミテッド 白癬を防止又は処置するための医薬組成物
KR102729906B1 (ko) * 2020-10-30 2024-11-14 주식회사 대웅제약 항진균제를 포함하는 안정화된 조성물
KR102301743B1 (ko) 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물
WO2022170147A1 (en) * 2021-02-05 2022-08-11 Acp Laboratories Llc Topical composition for treating fungi forming on a user's body
KR102863832B1 (ko) * 2021-05-04 2025-09-25 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물
WO2022235048A1 (ko) * 2021-05-04 2022-11-10 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물
KR20230158920A (ko) 2022-05-12 2023-11-21 주식회사한국파마 에피나코나졸을 함유하는 안정화된 국소투여용 약학 조성물
KR102842759B1 (ko) 2022-05-20 2025-08-06 주식회사한국파마 항진균제로서 에피나코나졸을 함유하는 약학 조성물
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE41306C (de) A. STORIE VAN DEN ABEELE in Brügge, Belgien Tabak-Trockner
US3655290A (en) 1970-10-02 1972-04-11 Griffith & Associates Inc Applicator instrument
US4052513A (en) 1974-12-13 1977-10-04 Plough, Inc. Stable topical anesthetic compositions
DE3106635A1 (de) 1981-02-23 1982-09-09 Bayer Ag Antimykotisches mittel mit hoher wirkstoff-freisetzung in form von stiften
US4384589A (en) 1981-07-27 1983-05-24 American Cyanamid Company Novel liquid delivery system for toiletries
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
EP0211555A3 (en) 1985-08-01 1988-06-08 Dow Corning Corporation Transparent silicone compositions
JPH01501143A (ja) 1985-11-04 1989-04-20 ダ−マトロジカル・プロダクツ・オブ・テキサス 爪への薬物の施用のための皮膜形成性製剤用ヴェヒクル、これらのヴェヒクルを基にした薬剤組成物および同じものの使用法
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US5208257A (en) * 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
JPS63188609A (ja) 1987-01-30 1988-08-04 Sansho Seiyaku Kk 着色を防止した外用剤
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5449715A (en) * 1991-09-17 1995-09-12 Isp Investments Inc. Colorless, non-toxic, stabilized aqueous solution of a C1-C5 alkyl vinyl ether and maleic acid copolymers
DK0625899T3 (da) 1992-02-12 1996-06-17 Janssen Cilag S P A Liposom-itraconazolformuleringer
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
GB9308103D0 (en) 1993-04-20 1993-06-02 Unilever Plc Cosmetic composition
WO1994026734A1 (fr) 1993-05-10 1994-11-24 Kaken Pharmaceutical Co., Ltd. Derive d'azolylamine
US5391367A (en) 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution
US5916545A (en) 1993-07-28 1999-06-29 Pfizer Inc. Antifungal nail solution
US5750137A (en) 1993-09-29 1998-05-12 Taskovich; Lina Tormen Monoglyceride/lactate ester permeation enhancer
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
JP3608209B2 (ja) 1993-10-27 2005-01-05 大正製薬株式会社 クロタミトン配合外用剤
FR2711898B1 (fr) 1993-11-05 1995-12-29 Oreal Pinceau pour appliquer du vernis à ongles, ou un produit analogue.
US6040266A (en) 1994-02-22 2000-03-21 Ultramet Foam catalyst support for exhaust purification
FR2717057B1 (fr) 1994-03-14 1996-04-12 Oreal Pinceau de vernis à ongles et ensemble d'application de vernis à ongles muni d'un tel pinceau.
US5487776A (en) 1994-03-17 1996-01-30 Nimni; Marcel Anti-fungal nail lacquer and method therefor
US6538039B2 (en) 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
WO1996007396A2 (en) 1994-09-07 1996-03-14 Johnson & Johnson Consumer Products, Inc. Retinoid compositions
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
WO1996030011A1 (en) 1995-03-30 1996-10-03 Bioplex, L.C. Topical antimycotic compositions
US5549930A (en) 1995-05-25 1996-08-27 Reysis; Moisei Dryer and top coat for nail polish
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US5696105A (en) 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
US5874069A (en) 1997-01-24 1999-02-23 Colgate-Palmolive Company Cosmetic composition containing silicon-modified amides as thickening agents and method of forming same
JP4227677B2 (ja) 1996-12-10 2009-02-18 杏林製薬株式会社 被膜形成性抗真菌剤組成物
AU6677698A (en) 1997-03-31 1998-10-22 Johnson & Johnson Consumer Companies, Inc. Solvent system for enhanced penetration of pharmaceutical compounds
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6197305B1 (en) 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
KR100269323B1 (ko) 1998-01-16 2000-10-16 윤종용 반도체장치의백금막식각방법
US5972358A (en) 1998-01-20 1999-10-26 Ethicon, Inc. Low tack lotion, gels and creams
US6022551A (en) 1998-01-20 2000-02-08 Ethicon, Inc. Antimicrobial composition
US5997893A (en) 1998-01-20 1999-12-07 Ethicon, Inc. Alcohol based anti-microbial compositions with cosmetic appearance
US20020022660A1 (en) 1998-01-20 2002-02-21 Hanuman B. Jampani Deep penetrating antimicrobial compositions
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
WO1999051192A2 (en) 1998-04-03 1999-10-14 Colgate-Palmolive Company Low residue cosmetic composition
US6306375B1 (en) 1998-05-01 2001-10-23 The Procter & Gamble Company Long wear nail polish having defined surface properties
US20030007939A1 (en) 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6264927B1 (en) 1998-08-27 2001-07-24 Elmer P. Monahan Topical solution and method for the treatment of nail fungus
DE59911740D1 (de) 1998-09-10 2005-04-14 Bioequal Ag Muttenz Topisch anwendbare mittel gegen nagelpilzerkrankungen
US7026308B1 (en) 1999-06-25 2006-04-11 The Procter & Gamble Company Topical anti-microbial compositions
CA2391274C (en) 1999-07-28 2010-12-14 Kaken Pharmaceutical Co., Ltd. Method for detecting pathogenic microorganism and antimicrobial agent, method for evaluating effect of antimicrobial agent, and antimicrobial agent
EP1199955A2 (en) 1999-07-30 2002-05-02 The Procter & Gamble Company Method for treating and preventing finger disorders
JP4780429B2 (ja) 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
US6433073B1 (en) 2000-07-27 2002-08-13 3M Innovative Properties Company Polyurethane dispersion in alcohol-water system
US6676953B2 (en) 2001-01-26 2004-01-13 Don L. Hexamer Antifungal composition and method for human nails
US6585963B1 (en) 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030039621A1 (en) 2001-04-10 2003-02-27 L'oreal Two-coat make-up product, its use and a kit containing the make-up product
US6664292B2 (en) 2001-06-04 2003-12-16 Mark H. Bogart Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
US6821508B2 (en) 2001-06-27 2004-11-23 Rutgers, The State University Composition and method for topical nail treatment
WO2003013447A2 (en) 2001-08-07 2003-02-20 Dow Corning Corporation Hair and skin care compositions containing siloxane-based polyamide copolymers
US7043791B2 (en) 2001-10-16 2006-05-16 Aubex Corporation Applicator
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
JP2004083439A (ja) 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd 爪用抗真菌外用剤
RU2329063C2 (ru) 2002-09-05 2008-07-20 Галдерма С.А. Раствор для применения в области ногтей и околоногтевого пространства
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US20050142094A1 (en) 2003-03-12 2005-06-30 Manoj Kumar Use of repeat sequence protein polymers in personal care compositions
US20040180025A1 (en) 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
ES2366273T3 (es) 2003-03-21 2011-10-18 Nexmed Holdings, Inc. Esmalte de uñas antifúngico y procedimiento de utilización.
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
GB2407496A (en) 2003-10-27 2005-05-04 Dow Corning Method for forming a polysiloxane film on a biological surface
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
EP1952808A3 (en) 2003-11-21 2008-09-03 Galderma Research & Development Composition in the form of a spray comprising calcitriol
WO2005065668A2 (en) 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
US7622844B1 (en) 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
US20050176650A1 (en) 2004-02-09 2005-08-11 Xanodyne Pharmacal, Inc. Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
US20060008538A1 (en) 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
US20070082039A1 (en) 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060165747A1 (en) 2005-01-24 2006-07-27 David Rolf Antifungal composition, method and kit for topically treating onychomycosis
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20060280706A1 (en) 2005-05-25 2006-12-14 L'oreal Rinse-off cosmetic composition containing interference particles
US20070071705A1 (en) 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
AU2006326388B2 (en) 2005-12-14 2013-01-24 Nuvo Research Inc. Compositions and methods for treating dermatological conditions
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
US20070207222A1 (en) 2006-03-01 2007-09-06 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20070207107A1 (en) 2006-03-03 2007-09-06 Gareth Winckle Silicone based emulsions for topical drug delivery
WO2007103555A2 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
JP5184341B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
US7950865B2 (en) 2006-03-21 2011-05-31 L'oreal Packaging and applicator device
JP5433881B2 (ja) 2006-04-03 2014-03-05 セヴァ アニマル ヘルス ピーティーワイ リミテッド 安定化ペントサンポリサルフェート（ｐｐｓ）製剤
WO2008001200A2 (en) 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
MXPA06008988A (es) 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
PT2116243E (pt) 2006-12-28 2010-10-26 Kaken Pharma Co Ltd Composição de gel para tratamento de micoses
WO2008124131A1 (en) 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2009263346A (ja) 2008-03-31 2009-11-12 Kose Corp カイネチンを含有する乳化型化粧料
MX2011008204A (es) 2009-02-05 2011-12-06 Targeted Delivery Technologies Ltd Metodos para reducir la proliferacion y viabilidad de los agentes microbianos.
EP2395839B1 (en) 2009-02-13 2014-05-07 Topica Pharmaceuticals, Inc Anti-fungal formulation
FR2942716B1 (fr) 2009-03-06 2011-04-15 Galderma Res & Dev Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle
JP2012533548A (ja) 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
WO2011045765A1 (en) * 2009-10-14 2011-04-21 Scuola Internazionale Superiore Di Studi Avanzati TEMPORALLY PATTERNED OVEREXPRESSION OF Foxg1 AND Emx2 TRANSCRIPTION FACTOR GENES IN NEURAL PRECURSORS FOR BRAIN TISSUE REPAIR
WO2011064558A2 (en) * 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
FR2954164B1 (fr) 2009-12-18 2012-03-16 Galderma Pharma Sa Composition antifongique destinee a etre appliquee sur l'ongle perfore
CA2799393A1 (en) * 2010-05-20 2011-11-24 Nam Woong Yang Skin preparation composition for external use with excellent antibacterial and antifungal effects
EP2588116A4 (en) 2010-06-29 2013-12-04 Merck Sharp & Dohme BY SUBSTITUTED BETA-CYCLODEXTRIN STABILIZED INTRAVENOUS POSACONAZOLE SOLUTION FORMULATIONS
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
PT2612859E (pt) * 2010-08-31 2015-11-30 Kaken Pharma Co Ltd Método para a produzir o derivado de 1-triazole-2-butanol
JP6005344B2 (ja) 2011-07-05 2016-10-12 科研製薬株式会社 爪白癬薬用塗布具
EP2748205A4 (en) * 2012-02-28 2014-07-30 Cydex Pharmaceuticals Inc ALKYLATED COMPOSITIONS BASED ON CYCLODEXTRIN AND METHOD FOR THE PREPARATION AND USE THEREOF
WO2015051183A1 (en) 2013-10-03 2015-04-09 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
KR20160087898A (ko) 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치

Also Published As

Publication number Publication date
CN105683184B (zh) 2019-05-10
AU2014329421B2 (en) 2018-08-02
US9662394B2 (en) 2017-05-30
MY179756A (en) 2020-11-12
US20150099785A1 (en) 2015-04-09
US20190358329A1 (en) 2019-11-28
PH12016500586A1 (en) 2016-05-23
JP2020169207A (ja) 2020-10-15
US12076404B2 (en) 2024-09-03
CA2924748C (en) 2019-09-03
CN110433291B (zh) 2023-04-28
US20170326240A1 (en) 2017-11-16
MX363386B (es) 2019-03-20
PH12016500586B1 (en) 2020-02-21
CN110433291A (zh) 2019-11-12
KR20160068812A (ko) 2016-06-15
IL244850A0 (en) 2016-05-31
US10864274B2 (en) 2020-12-15
AU2014329421A1 (en) 2016-04-07
MX2016004168A (es) 2016-09-08
CN105683184A (zh) 2016-06-15
IL244850B (en) 2020-04-30
EP3052487A4 (en) 2017-05-03
JP2016532722A (ja) 2016-10-20
EP3052487B1 (en) 2018-09-05
US20210205457A1 (en) 2021-07-08
KR102320051B1 (ko) 2021-10-29
CA2924748A1 (en) 2015-04-09
JP2019108388A (ja) 2019-07-04
EP3052487A1 (en) 2016-08-10
WO2015051183A1 (en) 2015-04-09
SG11201602596UA (en) 2016-04-28
JP6774518B2 (ja) 2020-10-28
US10342875B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
JP6516759B2 (ja) 安定化エフィナコナゾール組成物
KR101343291B1 (ko) 외용의 의약 조성물
EP2191826B1 (en) Pharmaceutical composition
JP6503303B2 (ja) 真菌感染の処置のための医薬組成物
ES2580480T3 (es) Agente antifúngico
JP2022113148A (ja) エフィナコナゾール外用組成物
HK40016945A (en) Stabilized efinaconazole compositions
HK40016945B (zh) 稳定的艾菲康唑组合物
WO2019070221A1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS OF LULICONAZOLE
JP6503627B2 (ja) 医薬液体組成物
JP5722364B2 (ja) 医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190307

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190320

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190416

R150 Certificate of patent or registration of utility model

Ref document number: 6516759

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250